



**LIMITED REVIEW REPORT FOR THE QUARTER AND HALF YEAR ENDED 30.09.2017**

**Review Report to The Board of Directors, Marksans Pharma Ltd.**

We have reviewed the accompanying statement of unaudited standalone financial results of MARKSANS PHARMA LTD for the quarter and half year ended 30<sup>th</sup> September, 2017 being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this financial statement based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not reviewed the accompanying unaudited financial results and other financial information for the comparative period as of and for the quarter and half year ended 30<sup>th</sup> September, 2016 which have been presented solely based on the information compiled by the management.

For V. S. LALPURIA & CO.  
Chartered Accountants

V. S. LALPURIA  
(Proprietor)  
M.No.015926  
Place: Mumbai  
Date: 13<sup>th</sup> November, 2017



**LIMITED REVIEW REPORT FOR THE QUARTER AND HALF YEAR ENDED 30.09.2017**

**Review Report to The Board of Directors, Marksans Pharma Ltd.**

We have reviewed the accompanying statement of unaudited consolidated financial results of MARKSANS PHARMA LTD for the quarter and half year ended 30<sup>th</sup> September, 2017 being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this financial statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not reviewed the financial results of Three (3) subsidiaries included in the consolidated financial statement, whose consolidated financial results reflect total revenues of Rs. 1983.97 million and Rs. 3670.65 million for the quarter and half year ended 30<sup>th</sup> September, 2017 respectively and net profit of Rs. 90.93 million and Rs.223.51 million for the quarter and half year ended 30<sup>th</sup> September, 2017 respectively.

We have not reviewed the accompanying unaudited financial results and other financial information for the comparative period as of and for the quarter and half year ended 30<sup>th</sup> September, 2016 which have been presented solely based on the information compiled by the management.

For V. S. LALPURIA & CO.  
Chartered Accountants

V. S. LALPURIA

(Proprietor)

M.No.015926

Place: Mumbai

Date: 13<sup>th</sup> November, 2017



MARKSANS PHARMA LIMITED

Registered Office: 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (West), Mumbai-400053 (CIN:L24110MH1992PLC0893964)  
 Telephone No.: 022-4001 2000, Fax No.: 022-4001 2011, E-mail: info@marksanspharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2017

(₹ in Million)

Sr. No.	PARTICULARS	3 MONTHS ENDED			6 MONTHS ENDED			3 MONTHS ENDED			6 MONTHS ENDED		
		30.09.2017	30.06.2017	30.09.2016	30.08.2017	30.09.2016	30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016		
1	Revenue from Operations	754.12	523.88	555.19	1,278.00	973.08	2,738.09	2,210.56	1,804.26	4,948.64	3,671.73		
2	Other Income	-	0.43	66.88	0.43	66.88	-	0.43	66.99	0.43	67.09		
3	Total Income	754.12	524.31	622.07	1,278.43	1,039.96	2,738.09	2,210.99	1,871.25	4,949.07	3,738.82		
4	Expenses												
	Cost of Material Consumed	391.90	272.93	349.03	664.84	544.65	1,077.55	1,064.97	913.87	2,142.52	1,827.03		
	Purchase of Stock - In-trade	49.78	25.81	10.02	75.59	32.99	551.53	394.68	234.45	946.20	584.14		
	Changes in Inventories of finished goods, work-in-process and Stock-in-Trade	27.24	(28.75)	(38.83)	(1.52)	(56.49)	132.74	(196.40)	(47.58)	(63.66)	(212.59)		
	Employee benefits expense	110.98	119.56	97.93	230.55	193.29	369.90	374.01	352.21	733.91	734.85		
	Finance cost	25.00	13.24	5.84	38.24	12.57	30.43	19.35	10.61	49.78	23.38		
	Depreciation and amortisation expense	33.13	38.06	37.48	71.20	74.18	69.75	74.46	58.99	144.21	107.18		
	Other expenses	110.56	55.94	140.56	166.50	157.18	370.45	283.35	349.47	653.81	601.78		
5	Total Expenses	748.59	486.78	602.03	1,245.40	958.37	2,592.35	2,014.42	1,872.02	4,606.77	3,665.77		
	Profit/(Loss) before tax (3-4)	5.53	27.52	20.04	33.03	81.59	145.74	196.57	(0.77)	342.30	73.05		
6	Tax expense:												
	(1) Current Year	5.81	4.58	2.00	10.39	5.00	55.09	41.05	2.09	96.15	5.09		
	(2) Earlier year	-	0.04	(11.78)	0.04	(11.78)	-	0.04	(11.78)	0.04	(11.76)		
	(3) Deferred tax	(13.45)	11.30	1.43	(2.15)	19.46	(13.45)	11.30	1.43	(2.15)	19.46		
	Total Tax Expenses	(7.64)	15.92	(8.35)	8.28	12.68	41.64	52.39	(8.28)	94.04	12.77		
7	Profit/(Loss) for the period (5-6)	13.17	11.60	28.39	24.75	68.91	104.10	144.18	7.49	248.26	60.28		
8	Other Comprehensive Income/(Loss)	-	-	-	-	-	-	-	-	-	-		
9	Total Comprehensive Income for the period	13.17	11.60	28.39	24.75	68.91	104.10	144.18	7.49	248.26	60.28		
10	Total Comprehensive Income attributable to												
	Non-controlling interests	-	-	-	-	-	9.87	7.80	0.69	17.66	9.16		
	Owners of the company	13.17	11.60	28.39	24.75	68.91	94.23	136.38	6.80	230.60	51.12		
11	Paid up Equity Share Capital (Face Value ₹1 each)	409.31	409.31	409.31	409.31	409.31	409.31	409.31	409.31	409.31	409.31		
12(a)	Earnings Per Share of ₹1 each	Basic	0.03	0.03	0.07	0.06	0.23	0.33	0.02	0.56	0.12		
	Diluted	0.03	0.03	0.07	0.06	0.17	0.23	0.33	0.02	0.56	0.12		



## STATEMENT OF ASSETS AND LIABILITIES

(₹ in Million)

Statement of Financial Position	STANDALONE	CONSOLIDATED
	AS AT 30.09.2017 UNAUDITED	AS AT 30.09.2017 UNAUDITED
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	887.20	1,836.76
Capital work in progress	5.28	5.28
Goodwill		657.52
Other Intangible assets	0.09	328.16
Intangible assets under development	-	-
<b>Financial Assets</b>		
(i) Investments	2,360.74	-
(ii) Loans and advances	5.89	54.33
(iii) Others Financial Assets	-	-
Deferred tax assets (net)	-	4.29
Other non-current assets	0.02	0.02
<b>Total Non-current assets</b>	<b>3,259.22</b>	<b>2,886.36</b>
<b>Current assets</b>		
Inventories	332.93	1,876.44
<b>Financial Assets</b>		
(i) Trade and other receivables	1,657.92	3,268.58
(ii) Cash and cash equivalents	16.13	256.84
(iii) Other Financial Assets	363.60	313.45
Current tax assets	-	-
Other current assets	-	-
<b>Total Current assets</b>	<b>2,370.58</b>	<b>5,715.31</b>
<b>Total assets</b>	<b>5,629.80</b>	<b>8,601.67</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	519.31	519.31
Other Equity	3,811.56	4,202.65
Minority Interest	-	82.54
<b>Liabilities</b>		
<b>Non-Current Liabilities</b>		
<b>Financial Liabilities</b>		
(i) Borrowings	-	-
(ii) Other financial liabilities	-	-
Deferred tax liabilities (Net)	7.47	-
Other non-current liabilities	-	-
<b>Total Non Current Liabilities</b>	<b>7.47</b>	<b>-</b>
<b>Current liabilities</b>		
<b>Financial Liability</b>		
(i) Borrowings	694.90	1,240.91
(ii) Trade Payable	346.93	2,002.14
(iii) Other financial liabilities	11.32	11.32
Other Current Liabilities	0.01	0.01
Provisions	195.22	409.80
Current Tax Liabilities ( Net)	43.08	132.99
<b>Total Current Liabilities</b>	<b>1,291.46</b>	<b>3,797.17</b>
<b>Total Liabilities</b>	<b>1,298.93</b>	<b>3,797.17</b>
<b>Total equity and liabilities</b>	<b>5,629.80</b>	<b>8,601.67</b>



**NOTES:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13<sup>th</sup> November, 2017
- 2 The Company has adopted Indian Accounting Standard (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. The date of transition to Ind AS is April 01, 2017 and accordingly, these unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" and other accounting principles generally accepted in India. The impact of transition has been accounted for in the opening reserves and the comparative period figures have been reinstated accordingly.
- 3 There is a possibility that these financial results may require adjustment before constituting the final Ind AS financial statements as of and for the year ending 31 March 2018 due to change in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or change in the use of one or more optional exemptions from full retrospective application as permitted under Ind AS 101.
- 4 The reconciliation of Net Profit as previously reported (referred to as "Previous GAAP") and Ind AS is as under:

Particulars	(` in Million)	
	3 MONTHS ENDED 30.09.2016	6 MONTHS ENDED 30.09.2016
Net Profit Under previous GAAP	25.88	32.14
Impact of foreign currency exchange differences	4.12	59.15
Impact on Deferred tax	(1.43)	(19.48)
Other Ind AS adjustments	0.02	(2.92)
Net profit for the period under Ind AS	28.39	68.91

- 5 The format for unaudited financial results as prescribed in SEBI's circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular CIR/CFD/FAC/62/2016 dated July 5, 2016 applicable to all companies that are required to comply with Ind AS.
- 6 The Consolidated Financial Statements Include Financial Statements of the subsidiaries Marksans Pharma (U.K.) Limited, Marksans Pharma Inc. USA and Nova Pharmaceuticals Australasia Pty Ltd.
- 7 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 8 Previous period's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current period's figures.

Place: Mumbai.  
Date: 13th November, 2017  
[www.marksanspharma.com](http://www.marksanspharma.com)



For MARKSANS PHARMA LIMITED

MARK SALDANHA  
Managing Director.